GTBP — GT Biopharma Balance Sheet
0.000.00%
- $5.93m
- -$3.88m
Annual balance sheet for GT Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 0.028 | 5.3 | 32 | 16.5 | 14 |
Prepaid Expenses | |||||
Total Current Assets | 0.274 | 5.66 | 32.2 | 16.6 | 14.1 |
Net Property, Plant And Equipment | 0.11 | 0 | — | 0.165 | 0.053 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 0.396 | 5.66 | 32.2 | 16.7 | 14.1 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 19.7 | 35.1 | 10.3 | 4.94 | 6.63 |
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 19.5 | 34.9 | 10.3 | 5 | 6.63 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | -19.1 | -29.3 | 21.9 | 11.7 | 7.48 |
Total Liabilities & Shareholders' Equity | 0.396 | 5.66 | 32.2 | 16.7 | 14.1 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |